Search Ontology:
ChEBI

AZD3965

Term ID
CHEBI:234329
Synonyms
  • 5-[(4S)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl]-3-methyl-6-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl}-1-(propan-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  • 5-{[(4S)-4-hydroxy-4-methyl-1,2-oxazolidin-2-yl]carbonyl}-3-methyl-6-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl}-1-(propan-2-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  • AZD 3965
  • AZD-3965
Definition
A thienopyrimidine that is thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione substituted by isopropyl, methyl, (4S)-4-hydroxy-4-methyl-1,2-oxazolidine-2-carbonyl, and [5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl groups at positions 1, 3, 5, and 6, respectively. It is an inhibitor of monocarboxylate transporter 1 (Ki = 1.6 nM), and was previously in phase I clinical trials for the treatment of lymphomas and solid tumours.
References
  • cas:1448671-31-5
  • pubmed:24277449
  • pubmed:25281618
  • pubmed:28385782
  • pubmed:28923861
  • pubmed:29050199
  • pubmed:29674138
  • pubmed:30617815
  • pubmed:31010842
  • pubmed:31823112
  • pubmed:31937921
  • pubmed:32076124
  • pubmed:32203218
  • pubmed:32529599
  • pubmed:32604836
  • pubmed:32833237
  • pubmed:33540599
  • pubmed:33963018
  • pubmed:35011413
  • pubmed:35618788
  • pubmed:36342616
  • pubmed:36652553
  • pubmed:36884092
  • pubmed:38140029
  • pubmed:39465441
  • pubmed:39810069
  • pubmed:39810250
  • pubmed:40043615
  • pubmed:40347782
  • pubmed:40400476
Ontology
ChEBI  ( EBI )
Relationships
Phenotype
Phenotype resulting from AZD3965
Phenotype where environments contain AZD3965
Phenotype modified by environments containing AZD3965
Phenotype affecting AZD3965
Human Disease Model